TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF ADVANCED THYROID CARCINOMA: REAL-LIFE MONOCENTRIC EXPERIENCE
Thyroid World Congress ePoster Library. Colombo C. 06/20/19; 272090; 150
Carla Colombo
Carla Colombo
Login now to access Regular content available to all registered users.

You may also access this content "anytime, anywhere" with the Free MULTILEARNING App for iOS and Android
Abstract
Rate & Comment (0)

PURPOSE: To report the efficacy and toxicity of TKIs treatment in real-life practice.



METHODS: Eighteen patients on Lenvatinib (n=12, 7 F, mean age 51 years) and Vandetanib (n=6, 3 F, mean age 41 years) in a single Center, with an average follow-up of 17.6 and 46.3 months, respectively. Response to treatment defined using the RECIST criteria. Adverse events assessed using the CTCAE 4.03 scale.



RESULTS: At the last follow up visit, progression-free survival is 22.1 and 51 months for Lenvatinib and Vandetanib, respectively. The best morphological response with Lenvatinib is a partial response (PR) in 9/12 and a stable disease (SD) in 3/12 patients; with Vandetanib, a PR in 3/6, a SD in 2/6 and a disease progression in 1/6 patients. During the follow up, the frequency of dose reduction, temporary discontinuation, or definitive withdrawal has been of 57%, 43%, and 0% with Lenvatinib and of 50%, 0% and 0% with Vandetanib.

Frequent shared adverse events were hyperthension (86% and 50% of patients on Lenvatinib and Vandetanib, respectively), diarrhea (85% of patients), treated with Loperamide; asthenia (85%), primary hypoadrenalism (39%); weight loss (69%) and anorexia (62%). Prolongation of the QT interval and rash were present in 50% of patients on Vandetanib.



CONCLUSIONS: Treatment with Lenvatinib and Vandetanib is effective, but hampered by a high rate of adverse events. The good therapeutic response and the low rate of dosage reduction or treatment discontinuation was achieved thanks to a close monitoring and careful management of adverse events by a multidisciplinary team.

 


PURPOSE: To report the efficacy and toxicity of TKIs treatment in real-life practice.



METHODS: Eighteen patients on Lenvatinib (n=12, 7 F, mean age 51 years) and Vandetanib (n=6, 3 F, mean age 41 years) in a single Center, with an average follow-up of 17.6 and 46.3 months, respectively. Response to treatment defined using the RECIST criteria. Adverse events assessed using the CTCAE 4.03 scale.



RESULTS: At the last follow up visit, progression-free survival is 22.1 and 51 months for Lenvatinib and Vandetanib, respectively. The best morphological response with Lenvatinib is a partial response (PR) in 9/12 and a stable disease (SD) in 3/12 patients; with Vandetanib, a PR in 3/6, a SD in 2/6 and a disease progression in 1/6 patients. During the follow up, the frequency of dose reduction, temporary discontinuation, or definitive withdrawal has been of 57%, 43%, and 0% with Lenvatinib and of 50%, 0% and 0% with Vandetanib.

Frequent shared adverse events were hyperthension (86% and 50% of patients on Lenvatinib and Vandetanib, respectively), diarrhea (85% of patients), treated with Loperamide; asthenia (85%), primary hypoadrenalism (39%); weight loss (69%) and anorexia (62%). Prolongation of the QT interval and rash were present in 50% of patients on Vandetanib.



CONCLUSIONS: Treatment with Lenvatinib and Vandetanib is effective, but hampered by a high rate of adverse events. The good therapeutic response and the low rate of dosage reduction or treatment discontinuation was achieved thanks to a close monitoring and careful management of adverse events by a multidisciplinary team.

 


    This eLearning portal is powered by:
    This eLearning portal is powered by MULTIEPORTAL
Anonymous User Privacy Preferences

Strictly Necessary Cookies (Always Active)

MULTILEARNING platforms and tools hereinafter referred as “MLG SOFTWARE” are provided to you as pure educational platforms/services requiring cookies to operate. In the case of the MLG SOFTWARE, cookies are essential for the Platform to function properly for the provision of education. If these cookies are disabled, a large subset of the functionality provided by the Platform will either be unavailable or cease to work as expected. The MLG SOFTWARE do not capture non-essential activities such as menu items and listings you click on or pages viewed.


Performance Cookies

Performance cookies are used to analyse how visitors use a website in order to provide a better user experience.


Save Settings